Oral clodronate in breast cancer patients with bone metastases: A randomized study

Journal of Internal Medicine

Volumn 246, Issue 1, 1999, Pages 67-74

  Kristensen, B ^a,b   Ejlertsen, B ^a   Groenvold, M ^a   Hein, S ^a   Loft, H ^a   Mouridsen, H T ^a  

^a FINSEN LABORATORY   (Denmark)

^b HILLERØD HOSPITAL   (Denmark)

Author keywords

Bone metastases; Breast cancer; Clodronate

Indexed keywords

ANALGESIC AGENT; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; PREDNISOLONE; SODIUM CHLORIDE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; FEMALE; HUMAN; HYPERCALCEMIA; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; ORAL DRUG ADMINISTRATION; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANALGESICS, NON-NARCOTIC; BONE NEOPLASMS; BREAST NEOPLASMS; CLODRONIC ACID; DISEASE PROGRESSION; FEMALE; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; SURVIVAL ANALYSIS;

EID: 0032798648     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.1999.00507.x     Document Type: Article

References (15)

1. Elomaa I, Blomqvist C, Porkka L, Holmström T, Taube T, Lamberg-Allardt C, Borgström GH. Clodronate for osteolytic metastases due to breast cancer. Biomed Pharmacother 1998; 42: 111-16.
2. van Holten-Verzantvoort ATM, Kroon HM, Bijvoet OLM, Cleton FJ, Beex LVAM, Blijham G et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol 1993; 11: 491-98.
3. Paterson AHG, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993; 11: 59-65.
4. Conte PF, Latreille J, Mauriac F, Calabresi F, Santos R, Campos D et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. J Clin Onrol 1996; 14: 2552-59.
5. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C et al. Efficiency of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996; 335: 1785-91.
6. Kanis JA, Powles T, Paterson AH, McCloskey EV, Ashley S. Clodronate decreases the frequency or skeletal metastases in women with breast cancer. Bone 1996; 19: 663-67.
7. Diel IJ, Solomayer E-F, Costa SD, Gollan C, Goerner R, Wallwiener D et al. Reduction in new metasstases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339: 357-63.
8. Kristensen B, Ejlertsen B, Holmegaard SN, Krarup-Hansen A, Transbol I, Mouridsen H. Prednisolone in the treatment of severe malignant hypercalcaemia in metastatic breast cancer: a randomized study. J Int Med 1992; 232: 237-45.
9. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ et al, The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-76.
10. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361-70.
11. George SL. The required size and length of a phase III clinical trial. In: Buyse ME, Staquet MJ, Sylvester RJ. eds. Cancer Clinical Trials. Methods and Practice. Oxford: Oxford Medical Publications, 1988; 287-310.
12. Marubini E, Valsecchi MG, Non-parametric methods for the comparison of survival curves. In: Marubini E, Valsecchi MG, eds. Analysing Survival Data from Clinical Trials and Observational Studies. New York: J. Wiley, 1995; 91-141.
13. Windeler J, Lange S. Events per person year - a dubious concept. Br Med J 1995; 310: 454-56.
14. Dodwell DJ. Malignant bone resorption: cellular and biochemical mechanisms. Am Oncol 1992; 3: 257-67.
15. Iveson TJ, Smith IE, Dowsett M. Pathogenesis of bone metastases in breast cancer. Breast 1993; 2: 70-78.